Responses
Clinical/translational cancer immunotherapy
Original research
Clinical outcomes of prexasertib monotherapy in recurrent BRCA wild-type high-grade serous ovarian cancer involve innate and adaptive immune responses
Compose a Response to This Article
Other responses
No responses have been published for this article.